Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcjo.2015.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib.
BMJ Case Rep
December 2019
Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). The incidence of ocular toxicities as adverse effects (AE) of erlotinib is relatively common. However, post-marketing, acute anterior uveitis (AAU) has been reported in a small number of cases as a putative AE resulting from erlotinib therapy.
View Article and Find Full Text PDFBilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases.
Am J Ophthalmol Case Rep
June 2017
Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA, USA.
Purpose: To report two new cases of presumed erlotinib-associated bilateral acute simultaneous-onset anterior uveitis effectively treated with topical steroids.
Observations: Two patients were referred to the uveitis clinic with bilateral acute simultaneous onset, anterior uveitis six weeks after starting the chemotherapeutic agent erlotinib. Frequent topical steroid were started and the inflammation responded swiftly and completely.
Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation.
Am J Ophthalmol Case Rep
December 2016
Department of Ophthalmology, University of Florida, College of Medicine, Jacksonville, FL, United States.
Purpose: We report a case of erlotinib-associated severe recalcitrant bilateral keratouveitis after uneventful corneal ethylenediaminetetraacetic acid (EDTA) chelation in a patient with non-small cell lung cancer (NSCLC); discontinuation of erlotinib led to complete resolution.
Observations: An elderly person presented with band keratopathy (BSK) of undetermined etiology in the both eyes, associated with foreign body sensation and constant tearing. The patient was on oral erlotinib treatment 150 mg PO daily for 1 year for NSCLC status post radiation therapy.
Erlotinib-associated acute pneumonitis: report of two cases.
Can Respir J
April 2007
Department of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Two cases of erlotinib-associated acute pneumonitis are described. The first patient was started on erlotinib treatment for metastatic non-small cell lung cancer. The second patient was treated with erlotinib for metastatic adenocarcinoma of unknown origin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!